Return on Tangible Equity (Quarterly)

Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity

BioCryst Pharmaceuticals, Inc. (BCRX) had Return on Tangible Equity of -1.21% for the most recently reported fiscal quarter, ending 2025-06-30.

Quarterly Annual

Figures for fiscal quarter ending 2025-06-30

Income Statement Financials
Revenue	$163.35M
Net Income	$5.08M
Cost of Goods Sold	$2.80M
Gross Profit	$160.56M
Operating Expenses	$133.57M
Operating Income	$29.79M
Non-Operating Income/Expense	$-23.30M
Pre-Tax Income	$6.49M
Normalized Pre-Tax Income	$6.49M
Income after Taxes	$5.08M
Income from Continuous Operations	$5.08M
Consolidated Net Income/Loss	$5.08M
Normalized Income after Taxes	$5.08M
EBIT	$29.79M
EBITDA	$28.96M
Weighted-Average Shares Outstanding (Basic)	209.52M
Weighted-Average Shares Outstanding (Diluted)	219.89M
Earnings per Share (EPS) (Basic)	$0.02
Earnings per Share (EPS) (Diluted)	$0.02
Balance Sheet Financials
Current Assets	$398.46M
Property, Plant, and Equipment	$8.46M
Long-Term Assets	$58.73M
Total Assets	$457.19M
Current Liabilities	$177.16M
Long-Term Debt	$692.68M
Long-Term Liabilities	$701.62M
Total Liabilities	$878.78M
Common Equity	$-421.59M
Tangible Shareholders Equity	$-421.59M
Shareholders Equity	$-421.59M
Common Shares Outstanding	209.91M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$13.79M
Cash Flow from Investing Activities	$56.22M
Cash Flow from Financial Activities	$-73.16M
Beginning Cash	$-15.06M
End Cash	$-16.40M
Increase/Decrease in Cash	$-1.34M
Stock-Based Compensation	$42.67M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	2.25
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	2.56
Debt to Equity Ratio	-1.73
Gross Margin	98.29%
Operating Margin	18.23%
EBIT Margin	18.23%
EBITDA Margin	--
Pre-Tax Profit Margin	3.97%
Profit Margin	3.11%
Free Cash Flow	$13.46M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.36
Inventory Turnover	0.55
Receiveable Turnover	1.79
Days Sales in Receivables	50.23
Return on Equity	-1.21%
Return on Tangible Equity	-1.21%
Return on Assets	1.11%
Return on Investments	1.88%
Book Value Per Share	$-2.01
Free Cash Flow per Share	$0.06
Operating Cash Flow per Share	$0.06

Data from Zacks Investment Research, Inc.